Key Takeaways
- A supply-shock quarter, not a demand problem: Revenue fell 26% YoY as syringe, stopper and API shortages choked dispatches, but management insists underlying demand stays strong and the worst cost pressures have already passed.
- Lost revenue of ₹250–300 crores is mostly unrecoverable: Syringe shortages alone cost ~₹165 crores across markets, and management concedes it is difficult to recover 100% of the lost quarter, making FY23 a lower-growth year.
- Gross margin improved despite the chaos: Gross margin rose 284 bps YoY to 56% because of a richer regulated-market mix and cost-optimization levers, while core EBITDA margin held at 31.5% QoQ even after absorbing air-freight and alternate power costs.
- The US Enoxaparin ramp is a bright spot: Quarterly sales surged from ₹47 crores to ~₹160 crores, annualizing at ₹600–620 crores, as syringe allocation finally unlocked a contract that had been waiting for supply.
- What to watch next quarter: Whether BD syringe deliveries actually normalize in September, whether the heparin stopper alternative arrives before November, and whether the biologics CDMO lands its first revenue dollar by Q4.
The Supply Chain Breakdown
- Syringe shortages were the dominant disruption: A single-supplier contract for ~5 crore syringes per year (tied to a safety device for the US) went nearly dry for six to seven months, forcing Gland to prioritize US contractual commitments and walk away from domestic and RoW orders where alternate-syringe economics did not work.
- The revenue damage was concentrated and large: Lost syringe-driven revenue is pegged at ₹25 crores in the US, ₹100 crores in RoW, and ₹40 crores in domestic, while heparin stopper shortages from West added another ₹40–50 crores of lost sales.
- Stopper shortages are narrow but sticky: Only five or six stoppers out of ~150 products are affected, but stopper compatibility is product-specific and R&D-determined, so substitution is not trivial; the West schedule points to November, and Gland is trying to find an alternative sooner.
- Production-line shutdowns added self-inflicted downtime: Two Dundigal lines were shut during the quarter for modifications to mitigate bottlenecks, costing ~7–8% of available lyo and liquid vial capacity; both lines became operational from July and the lost production is expected to be covered over the next three quarters through improved productivity.
- Micafungin went to zero on customer destocking: Q1 FY23 had nil supply versus ₹126 crores in Q1 FY22 because the partner is liquidating inventory, but end-market sales by the partner are consistent, so this is a timing issue expected to reverse in a quarter or so.
- India revenue collapsed on a mix of base effects and economics: Sales fell from ~₹200 crores in Q4 FY22 to ~₹51 crores in Q1 FY23; last quarter included ~₹100 crores of low-margin Enoxaparin third-party supplies that were discontinued because increased import costs, logistics costs and dollar movement made them uneconomical under price control, while Q1 FY22 had ~₹80 crores of one-time COVID product sales now absent.
Srinivas Sadu: "I must say it is a tough start to FY'23 with few supply chain issues, which were ongoing for the last couple of quarters, hit us hard on a quarterly dispatches."
Demand: Strong Where It Could Be Served
- The core message is that demand is intact: Management repeatedly framed the quarter as a supply problem, not a demand problem, pointing to strong tender wins in RoW, surging US product volumes where syringes were available, and a domestic Insulin line where demand remains robust.
- Enoxaparin US is the proof case: Sales grew from ₹47 crores in Q4 to ~₹160 crores in Q1 once syringe allocation allowed Gland to supply under a contract that had been in place for years but unfilled; the annualized run-rate now sits at ₹600–620 crores versus ~₹250 crores for the full prior year.
- Other US molecules showed sharp growth: Ketorolac grew ~90%, and six or seven molecules grew 90–200%, though Vancomycin total market remains 30–35% below pre-COVID levels partly due to a shift to RTUs.
- RoW demand is contractually visible: Most tenders are won for a couple of years, so growth is constrained only by supply, not demand; management anticipates another quarter to return to normalized inventory levels for RoW.
- India Insulin demand is strong enough to recover lost production: The dedicated Insulin line was shut for modifications during the quarter, but management expects improved productivity over the rest of the year to cover the loss.
Srinivas Sadu: "Primarily it's a supply chain issue... The good aspect is that the demand stays strong."
Margin Resilience & Cost Absorption
- Gross margin improved 284 bps YoY to 56%: The expansion came from a higher percentage of sales from regulated markets, a favorable business-model mix, and a focus on optimizing cost levers, even as the top line shrank 26%.
- Core EBITDA margin held at 31.5% QoQ: This was achieved despite absorbing a 53% YoY increase in power and fuel costs (driven by tariff hikes and shortages forcing alternate utility use), air-freighting of goods due to material shortages, and a 22% YoY rise in manpower costs from recruitment and annual increments.
- Management calls the worst done on costs: The power situation has normalized and costs are expected to come down; other expenses at ₹80.8 crores actually declined sequentially from ₹89.9 crores in March, with only power and fuel rising substantially.
- The injectable cost structure creates operating leverage: Most of the cost in injectable facilities is fixed, so when sales volumes recover, margins should expand; management guided to 33–35% overall margins (excluding other income) over the next two years, driven by complex product approvals and leveraging newly added lines where fixed costs are already in place.
- Biologics CDMO is a ₹15 crore quarterly cost drag for now: The team is fully staffed and this operational-cost run rate is expected to continue for the next one to two years, with first revenue possible in Q4 FY23 if discussions progress well but not meaningfully adding to near-term numbers.
Srinivas Sadu: "I would say, it is one of the toughest quarters in terms of everything, right, I mean, the costs of utilities are high, power shortages in our states are very high, so we have to use utility for that. And then, we have to airlift lot of goods because of the shortages of materials. So that has been absorbed. So I would say, the worst things have already happened."
US Market: Launches, Pricing & Portfolio Shift
- New products are the growth engine: New products contributed about 4% to US sales in the quarter, and many were launched only in May or June so their contribution was not fully recognized; three more products are approved and planned for launch, with four additional products having goal dates in the next month, together addressing a ~$1.3 billion market.
- Price erosion is a manageable 1% impact: End-market price pressure percolates through profit share, but overall revenue from profit-share products is only about 10% of total, so even a larger fall at the end-market level does not materially move Gland's needle.
- CGT exclusivity on Zinc Sulfate adds a near-term tailwind: Gland was granted 180-day CGT exclusivity from the first commercial marketing date of 27 June 2022, and more exclusivities are expected in the next few quarters.
- The Enoxaparin contract transition is now complete: The partner had been taking supply from the innovator under a license Gland granted until Gland got its own product approval; now Gland is supplying directly and is confident of maintaining market share in the second half.
- Syringe allocation prioritized the US: Penalties normally exist for supply shortfalls but Gland is not losing anything on the US side; the cost was borne by domestic and RoW markets that were not catered.
Supply-Chain Fixes in Progress
- BD syringe capacity is expected online by September: The supplier has added new capacities after a gap of six to seven months of low supply; delivery schedules for the current quarter are in hand and management is comfortable on the US side, though a couple of million syringes may still be tight.
- Alternative syringe suppliers are being qualified for RoW: A Chinese supplier and an Italian supplier are in qualification; for domestic and some RoW markets using glass syringes, replacement can happen quickly, but for more regulated markets like Brazil or Saudi, data submission is required and that may take three to four months.
- Heparin stopper resolution is further out: The schedule from West is November, and Gland is trying to find an alternative stopper sooner, but stopper compatibility is product-specific so substitution requires R&D work.
- Dundigal line modifications are complete: Both lines became operational from July, and the production loss is expected to be covered over the next three quarters through improved productivity.
- API and primary packing material shortages should relax: Management expects the situation to ease over the next couple of quarters.
Strategic Build-Out: Biologics CDMO, Complex Injectables & China
- Biologics CDMO is in early customer-conversion mode: Four customers were engaged during the quarter (three new, one known customer with a different division), with discussions spanning technology transfer for clinical batches, analytical development, and one client looking to take a line for two months; initial contracts are expected to be small, project-based or one-year engagements, with some converting to commercial scale after clinicals and phase-III batches.
- Complex injectable manufacturing lines are installed: Lines for microspheres and combi-vials are being evaluated, and significant progress has been made in building internal capabilities and exploring external partnerships.
- China is moving toward first revenue: Two products had their facility inspection waived and are in the clearance phase, with first revenue expected in Q3 or Q4 FY23; five products are filing in FY23 and six to seven in FY24, and the next set of products has an addressable market size of USD 100 crores.
- M&A appetite is growing as valuations become more reasonable: Management has evaluated a number of targets and sees current market dynamics making target-asset valuations more reasonable, providing impetus to acquiring the right strategic fit.
- R&D spend will stay around 4% of revenue: Even for complex products, partners pitch in on studies, so R&D expense is not expected to increase dramatically.
Srinivas Sadu: "What happens with this is initially, people want to test waters, right, I mean, these are all new businesses we're entering, new technology we're entering. So they would like to give us smaller contracts for a year or so or it could be a project-based thing. And some of these gets converted to commercial scale after they do the clinicals and they come back to us for phase-III clinical batches and stuff like that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Supply-chain normalization | API and primary packing material shortages to relax | Next couple of quarters |
| Syringe supply normalization | BD capacity additions online; delivery schedules for current quarter in hand | September 2022 (BD capacity online) |
| Heparin stopper supply | West schedule for resolution; alternative being sought sooner | November 2022 |
| Dundigal production recovery | Lost production from line shutdowns covered through improved productivity | Next three quarters |
| RoW inventory normalization | Return to normalized inventory levels | Another quarter |
| Micafungin supply resumption | Customer inventory liquidation to reverse | A quarter or so |
| China first revenue | Two products in clearance phase | Q3 or Q4 FY23 |
| Biologics CDMO first revenue | First dollar possible if discussions go well; not meaningful near-term | Last quarter FY23 (possible, if discussions go well) |
| Full-year CAPEX | ₹300 crores on microsphere/combi line, complex injectables, API capacity, bag line | FY23 |
| Full-year margins (ex-other-income) | Expected around current quarter's range | FY23 |
| Two-year margin target (ex-other-income) | 33–35% overall, driven by complex approvals and operating leverage on new lines | Next two years |
| Biologics CDMO operational cost run rate | ₹15 crores per quarter | Next one to two years |
| R&D spend | Remain around 4% of revenue | Ongoing |
| Fosun relationship | No change in strategic view; Gland operates independently, no inter-company deposits | Ongoing |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue from operations | ₹856.9 cr, declined 26% YoY |
| Gross margin | 56%, improvement of 284 bps YoY |
| EBITDA | ₹344.3 cr, EBITDA margin of 37% |
| Core EBITDA margin | 31.5% |
| Net profit | ₹229.2 cr, PAT margin of 25% |
| Other income | ₹74.4 cr, includes forex gains of ₹34.2 cr and interest on fixed deposits of ₹37.6 cr |
| Effective tax rate | 25.7% |
| Cash flow from operations | ₹332.9 cr |
| Cash and equivalents | ₹3,789.2 cr as on June 30, 2022 |
| Total CAPEX incurred | ₹41.4 cr; full-year guidance maintained at ₹300 cr |
| R&D expenditure | ₹41 cr, 4.8% of revenue; ex-capital R&D at 4.1% of revenue |
| US market revenue growth | ~4% QoQ, degrowth of 4% YoY |
| Core markets revenue share | 82% of Q1 FY23 revenue vs 65% in Q1 FY22 |
| Rest of the world markets revenue share | 12% of Q1 FY23 revenue vs 19% in Q1 FY22 |
| India market revenue share | 6% of Q1 FY23 revenue |
| Profit share as percentage of revenue | ~10% |
| Cash conversion cycle | 241 days, same as Q1 FY22 |
| ROCE (ex-cash basis) | 21% |
| ANDA filings in the US | 316 as on June 30, 2022 |
| Product registrations globally | 1,567 as on June 30, 2022 |
| ANDA filings completed during Q1 FY23 | 6 |
| Product SKUs launched during Q1 FY23 | 14 |
| Biologics CDMO operational cost in P&L | ₹15 cr for the quarter; expected quarterly run rate for next one to two years |
| Power and fuel cost increase | 53% YoY, 36% QoQ |
| Manpower cost increase | 22% YoY; staff cost at ₹98 cr, confirmed as normalized base |
| Estimated sales loss from supply disruptions | ~₹250 cr in the quarter, difficult to recover 100% |
| Enoxaparin US sales | ~₹160 cr in Q1 FY23 vs ~₹47 cr in Q4 FY22 |
| Full-year margin guidance (ex-other-income) | Around current quarter's range; next two years target 33% to 35% |